Join industry leaders from @Curi_Bio @G2Gconsulting GCWC Capital, @HSBC and @lakestreetcm for insightful sessions focused on the life science fundraising landscape. Register for our October 27 Greater LA CEO Summit today: bit.ly/4xHAxhP #BiocomCEOSummit

A mentor’s experience can change the trajectory of an aspiring professional's career. The transition from college into the life science industry is a defining moment, and having dedicated guidance can make a meaningful difference. Through @BiocomInstitute's Life Science Career Fellowship program, mentors have the opportunity to guide emerging talent as they take their initial steps into the workforce. In our 2026 cohort, the percentage of fellows reporting strong confidence in pursuing life science careers jumped from 39% to 86%, while 95% of mentors agreed that fellows left the program fully prepared to seize new opportunities in the industry. With a flexible, six-month hybrid commitment totaling just 15 hours from January through June, mentoring offers a meaningful way to strengthen leadership skills, gain fresh perspectives and help build California’s life science workforce. Register to help guide the industry's rising talent: bit.ly/4d1P1Bw

AI is moving from experiment to operating model across life science. While 85% of surveyed organizations expect to increase agentic AI investment, only 22% report successfully scaling AI today. The next phase will be defined not by who experiments with AI, but by who can translate it into meaningful scientific and operational results. Explore the forces shaping California life science in Biocom’s 2026 Life Science Economic Impact Report: bit.ly/4uXG7uN

A therapy that works at the bench still has to be manufacturable. GeneFab CEO Philip Lee, Ph.D., discusses why scale should be considered early, how synthetic biology is changing the CDMO model and what’s ahead for in vivo therapies. Meet GeneFab and explore why designing for scale starts long before the manufacturing stage: bit.ly/4yfODbj

Partnering is officially open for @MedTechCon Hosted by @AdvaMedUpdate on October 18 – 21, this conference brings together more than 4,000 executives, innovators, investors, clinicians, regulators and policy leaders from 40+ countries. With 1,800+ companies represented, partnering gives you the opportunity to identify potential investors, customers, collaborators and strategic partners in Boston before you arrive. Register now to secure your spot and start scheduling one-on-one meetings before calendars fill up: bit.ly/4ykCy4v #MTC26 #medtech #MTC26HostPartner

This week in Bay Area life sciences: @ElixirMed receives regulatory approval in Japan for the DynamX Coronary Bioadaptor System. @RevMedicines receives FDA breakthrough therapy designation for daraxonrasib in combination with chemotherapy for first-line metastatic pancreatic cancer. #SantaAnaBio doses the first subjects in a Phase 1 study of SAB01 for the treatment of autoimmune inflammatory diseases. @TenayaThera receives FDA RMAT designation for TN-401 in PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Subscribe to receive the next newsletter in your inbox: bit.ly/40rlR8a

Explore where AI is having meaningful impact across biotech at our San Diego CEO Summit on October 8. Learn how leading organizations are using AI to accelerate drug development, improve efficiency and compress timelines across R&D, clinical development and enterprise operations. Register here: bit.ly/3TPZKZl

Step away from the lab and join us for the 2026 @fishersci New Technology Show on Wednesday, September 30, at 11:00 a.m. at The Forum in South San Francisco. Explore breakthrough instruments and technologies from 35+ leading laboratory suppliers, connect directly with product specialists and discover new solutions to streamline your workflows. Lunch will be provided during the show, followed immediately by a happy hour hosted by Biocom. Reserve your spot today: bit.ly/3VahxLb

This month in Greater Los Angeles life sciences: @GileadSciences reports that its non-virology pipeline across oncology and inflammatory diseases has officially reached "critical mass" in research allocation. @Amgen announces Phase 3 DeLLphi-305 results for IMDELLTRA in combination with durvalumab in first-line extensive-stage small cell lung cancer. #ArmataPharmaceuticals receives FDA breakthrough therapy designation for AP-SA02. #DualitasTherapeutics enters a multi-year research collaboration with Roche to discover bispecific antibodies for autoimmune and inflammatory disorders. Subscribe to receive the next newsletter in your inbox: bit.ly/3WFbOLh

This week in San Diego life sciences: @Hologic partners with The White Dress Project to bring fibroid education and patient voices to the Empowerment Experience. @bhtherapeutics presents updated Phase 1/2 SOLARA trial data demonstrating encouraging anti-tumor activity for BH-30643 in EGFR C797S-positive non-small cell lung cancer. @carlsmed files a patent infringement lawsuit against DeGen Medical. @VivoSimSolana presents new NAMkind drug toxicity data demonstrating predictive superiority in liver and gastrointestinal safety across small molecules and ADCs. Subscribe to receive the next newsletter in your inbox: bit.ly/4iqn5b1

Meet the speakers providing valuable insights at our San Diego HR Conference for Life Science on September 30. Register today: bit.ly/4hiOgVV #BiocomHRConf

Biocom member GeneFab partners with Axiom Biosciences to expand Axiom’s manufacturing and clinical development capabilities as it advances its therapeutic pipeline. Through the collaboration, GeneFab will provide development and manufacturing support focused on scalable, reproducible production processes designed to meet the quality and regulatory requirements of clinical-stage development. Learn more: bit.ly/4rs1xjP

Biocom is proud to join the Personal AI Health Alliance (PAIHA) to help advance intelligent wearables and personal AI in health care. We look forward to contributing to the conversation and connecting Biocom members with emerging ideas shaping more continuous, proactive and personalized care. Learn more: PAIHealth.org

It's time to welcome our new members! #WelcometoBiocom, #CatalYm develops immunotherapies for solid tumors, targeting and neutralizing GDF-15 to reverse cancer therapy resistance and enhance anti-PD-1 efficacy. #DigitalBiotechnologies is engineering the first solid-state next-generation sequencing platform designed specifically for clinical medicine. @enzenebio provides end-to-end biologics development, manufacturing and supply services. Inapill develops first-in-class, orally available small molecule therapeutics targeting immunometabolism to treat inflammatory, autoimmune and age-related diseases. #MiteraBiosciences develops investigational therapeutics as alternatives to traditional immunosuppressive treatments for autoimmune and alloimmune disorders. #PrimaryBioscience is designing a single-molecule protein sequencing device for comprehensive, multibiomarker screening.

Meet the industry leaders sharing their perspectives during our Bay Area CEO Summit session, VC Insights: Panel Discussion & Town Hall. Join us in Sonoma on October 23: bit.ly/3TieaB8

It's time to welcome our new members! #WelcometoBiocom, #Antogen provides immunopeptidomics services to identify and quantify peptide–HLA ligands from biological samples, supporting discovery and translational research in oncology, immunotherapy development and autoimmune disease. #Invizix develops noninvasive bioelectronic therapies using a waveform discovery engine and bedside delivery device designed to treat chronic disease during sleep. #Pastør21 AI deploys high-throughput sequencing and explainable AI to deliver pathogen intelligence and track antimicrobial-resistant bacterial strains. #RosemanBioventures provides startups and emerging life science companies in Las Vegas with turnkey laboratories, research infrastructure, regulatory guidance and connections to investors and industry partners to accelerate commercialization. #Stormlight is developing a therapeutic platform designed to gain biological control over cancer’s adaptability and overcome therapy-resistant malignancies. @wieldtx develops treatments for autoimmune diseases by combining human genetic validation with genetic and multi-omic data to identify targets involved in the root causes of inflammation.

Don't miss our San Diego HR Conference for Life Science on September 30, where our speakers will explore HR’s evolving role in fundraising and investor readiness, M&A and cultural integration, build vs buy decisions in biotech scaling, and more. Register here: bit.ly/4hdkyBB

Applications are open for the @bmsnews 2026 Golden Ticket Contest at MBC BioLabs. Up to two biotech startups will receive one year of lab space to advance research in oncology, hematology, immunology, cardiovascular disease or neuroscience. Apply by September 30: bit.ly/4rqhuae

Explore the executive conversations happening at our Greater LA CEO Sumit on October 27. Join us to gain valuable insights and candid perspectives from industry leaders. bit.ly/4hwLe1H

Discovery is only the beginning. Investment helps life science companies move from research → validation → clinical development → scale → commercialization, turning scientific possibility into real-world impact. That journey is a critical part of the life science engine in California. Explore Biocom’s 2026 Life Science Economic Impact Report for more: bit.ly/4uXG7uN